<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470-7330-14-S1-O32</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-O32</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Hybrid imaging with PET/CT and PET/MR</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Kjaer</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>akjaer@sund.ku.dk</email></contrib></contrib-group><aff id="I1"><label>1</label>Dept. of Clinical Physiology, Nuclear Medicine &#x00026; PET, Rigshospitalet, University of Copenhagen, 2000 Copenhagen, Denmark</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>O32</fpage><lpage>O32</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Kjaer; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Kjaer; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/O32"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title/><p>Hybrid PET/MRI systems have recently become commercially available with potential to change medical imaging by providing combined anatomical-metabolic image information. Especially in cancer patients, this may be of benefit.</p><p>PET itself is widely used in everyday routine due to its capability of providing molecular information used mainly for the non-invasive characterization of tumors and metastases [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>], as well as for monitoring effect of cancer therapy [<xref ref-type="bibr" rid="B3">3</xref>]. However, PET images contain no detailed anatomical information and, therefore benefits from fusion with morphological image information from CT. Accordingly, since PET/CT systems became available oncological PET examinations have mainly been performed as combined PET/CT which has been proven of higher diagnostic value than separate PET or CT imaging in a number of clinical indications [<xref ref-type="bibr" rid="B4">4</xref>]. Recently, hybrid PET/MRI scanners were introduced and made available. However, PET/MRI is more costly and with a lower throughput than PET/CT. Accordingly, the question arises when and if PET/MRI should be used in cancer patients. MRI has the advantages compared to CT, that it may also be considered a functional imaging technique in addition to its anatomical capabilities. This may be of particular relevance in cancer patients in view of need for planning tailored therapy and for monitoring response to treatment [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Compared to CT, also the anatomical capabilities of MRI are often superior due to better soft-tissue contrast.</p><p>The knowledge obtained from molecular imaging-guided therapies e.g. using FDG-PET for predicting therapy response in lymphomas [<xref ref-type="bibr" rid="B7">7</xref>], could quickly be transferred to PET/MRI, for a combined multi-parametric strategy. Accordingly, hybrid PET/MRI scanners might become game-changers for how MRI is used in clinical routine.</p><p>At the Department of Clinical Physiology, Nuclear Medicine &#x00026; PET at Rigshospitalet in Copenhagen we have currently PET/MRI scanned more than 1,200 patients and our experience so far will be presented and discussed with focus on whether PET/MRI fulfills a real clinical need within oncology or should (still) be considered an expensive research tool and the challenges of PET/MRI [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Kjaer</surname><given-names>A</given-names></name><article-title>Molecular imaging of cancer using PET and SPECT</article-title><source>Adv Exp Med Biol</source><year>2006</year><volume>587</volume><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1007/978-1-4020-5133-3_21</pub-id><?supplied-pmid 17163171?><pub-id pub-id-type="pmid">17163171</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Gambhir</surname><given-names>SS</given-names></name><article-title>Molecular imaging of cancer with positron emission tomography</article-title><source>Nature Rev Cancer</source><year>2002</year><volume>2</volume><issue>9</issue><fpage>683</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1038/nrc882</pub-id><pub-id pub-id-type="pmid">12209157</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Wahl</surname><given-names>RL</given-names></name><name><surname>Jacene</surname><given-names>H</given-names></name><name><surname>Kasamon</surname><given-names>Y</given-names></name><name><surname>Lodge</surname><given-names>MA</given-names></name><article-title>From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors</article-title><source>J Nucl Med</source><year>2009</year><volume>50</volume><issue>Suppl 1</issue><fpage>122S</fpage><lpage>150S</lpage><?supplied-pmid 19403881?><pub-id pub-id-type="pmid">19403881</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Delbeke</surname><given-names>D</given-names></name><name><surname>Schoder</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>WH</given-names></name><name><surname>Wahl</surname><given-names>RL</given-names></name><article-title>Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions</article-title><source>Sem Nucl Med</source><year>2009</year><volume>39</volume><issue>5</issue><fpage>308</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2009.03.002</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Padhani</surname><given-names>AR</given-names></name><name><surname>Koh</surname><given-names>DM</given-names></name><name><surname>Collins</surname><given-names>DJ</given-names></name><article-title>Whole-body diffusion-weighted MR imaging in cancer: current status and research directions</article-title><source>Radiology</source><year>2011</year><volume>261</volume><issue>3</issue><fpage>700</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1148/radiol.11110474</pub-id><?supplied-pmid 22095994?><pub-id pub-id-type="pmid">22095994</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Padhani</surname><given-names>AR</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Koh</surname><given-names>DM</given-names></name><name><surname>Chenevert</surname><given-names>TL</given-names></name><name><surname>Thoeny</surname><given-names>HC</given-names></name><name><surname>Takahara</surname><given-names>T</given-names></name><name><surname>Dzik-Jurasz</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>BD</given-names></name><name><surname>Van Cauteren</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>D</given-names></name><name><surname>Hammoud</surname><given-names>DA</given-names></name><name><surname>Rustin</surname><given-names>GJ</given-names></name><name><surname>Taouli</surname><given-names>B</given-names></name><name><surname>Choyke</surname><given-names>PL</given-names></name><article-title>Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations</article-title><source>Neoplasia</source><year>2009</year><volume>11</volume><issue>2</issue><fpage>102</fpage><lpage>125</lpage><?supplied-pmid 19186405?><pub-id pub-id-type="pmid">19186405</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Hutchings</surname><given-names>M</given-names></name><name><surname>Loft</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>LM</given-names></name><name><surname>Buhl</surname><given-names>T</given-names></name><name><surname>Jurlander</surname><given-names>J</given-names></name><name><surname>Buus</surname><given-names>S</given-names></name><name><surname>Keiding</surname><given-names>S</given-names></name><name><surname>D'Amore</surname><given-names>F</given-names></name><name><surname>Boesen</surname><given-names>AM</given-names></name><name><surname>Berthelsen</surname><given-names>AK</given-names></name><name><surname>Specht</surname><given-names>L</given-names></name><article-title>FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma</article-title><source>Blood</source><year>2006</year><volume>107</volume><issue>1</issue><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-06-2252</pub-id><?supplied-pmid 16150944?><pub-id pub-id-type="pmid">16150944</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Kj&#x000e6;r</surname><given-names>A</given-names></name><name><surname>Loft</surname><given-names>A</given-names></name><name><surname>Law</surname><given-names>I</given-names></name><name><surname>Berthelsen</surname><given-names>AK</given-names></name><name><surname>Borgwardt</surname><given-names>L</given-names></name><name><surname>L&#x000f6;fgren</surname><given-names>J</given-names></name><name><surname>Johnbeck</surname><given-names>CB</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>Keller</surname><given-names>S</given-names></name><name><surname>Holm</surname><given-names>S</given-names></name><name><surname>H&#x000f8;jgaard</surname><given-names>L</given-names></name><article-title>PET/MRI in cancer patients: first experiences and vision from Copenhagen</article-title><source>MAGMA</source><year>2013</year><volume>26</volume><issue>1</issue><fpage>37</fpage><lpage>47</lpage><comment>doi: 10.1007/s10334-012-0357-0. Epub 2012 Dec 25. PubMed PMID: 23266511</comment><pub-id pub-id-type="doi">10.1007/s10334-012-0357-0</pub-id><?supplied-pmid 23266511?><pub-id pub-id-type="pmid">23266511</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Keller</surname><given-names>SH</given-names></name><name><surname>Holm</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>Sattler</surname><given-names>B</given-names></name><name><surname>Andersen</surname><given-names>F</given-names></name><name><surname>Klausen</surname><given-names>TL</given-names></name><name><surname>H&#x000f8;jgaard</surname><given-names>L</given-names></name><name><surname>Kj&#x000e6;r</surname><given-names>A</given-names></name><name><surname>Beyer</surname><given-names>T</given-names></name><article-title>Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI</article-title><source>MAGMA</source><year>2013</year><volume>26</volume><issue>1</issue><fpage>173</fpage><lpage>81</lpage><comment>doi: 10.1007/s10334-012-0345-4. Epub 2012 Sep 21. PubMed PMID: 22996323</comment><pub-id pub-id-type="doi">10.1007/s10334-012-0345-4</pub-id><?supplied-pmid 22996323?><pub-id pub-id-type="pmid">22996323</pub-id></mixed-citation></ref></ref-list></back></article>
